Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGELLAN-AMD aflibercept biosimilar vs Eylea in nAMD
2019-003923-39Phase 3Completed
- Sponsor
- Bioeq AG
- Start
- Jan 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baiama in exudative macular degeneration (2 arms), sponsored by Bioeq AG. Primary endpoint: Change in BCVA at week 8. Started Jan 2020; status: completed.
02
Drugs
baiama
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2019-003923-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003923-39.